Promising Nephrotic Syndrome Treatments: A Look into the Future

Nephrotic syndrome is a complex renal disorder marked by excessive protein loss in the urine (greater than 40 mg/m²/hour), resulting in hypoalbuminemia (serum albumin below 30 g/L). This imbalance contributes to hyperlipidemia, edema, and a spectrum of systemic complications. The condition presents across age groups, with nephrotic syndrome in children often differing in etiology and response to therapy compared to nephrotic syndrome treatment in adults, underscoring the need for tailored clinical approaches.

From an epidemiological standpoint, nephrotic syndrome assessment is critical to understanding its prevalence, patient distribution, and overall disease burden. Comprehensive evaluations rely on well-defined assumptions to distinguish between primary and secondary glomerular disorders, which collectively shape the clinical and economic impact of the disease, including trends in the US proteinuria treatment market.

The total diagnosed prevalent cases of nephrotic syndrome in the 7MM were ~800,000 in 2025. These cases are expected to increase during the forecast period (2026–2036) due to rising cases of diabetes and hypertension, key risk factors for secondary nephrotic syndrome. Improved diagnostic techniques and increased awareness are also contributing to higher detection rates, leading to more identified cases in clinical practice.

The nephrotic syndrome treatment approach focuses on addressing the underlying causes of nephrotic syndrome while reducing nephrotic syndrome symptoms and preventing complications. Effective management of nephrotic syndrome may differ across populations, with specific strategies for nephrotic syndrome in children and tailored nephrotic syndrome treatment in adults. Physicians typically recommend a combination of medications for nephrotic syndrome, dietary modifications, and supportive care as part of comprehensive nephrotic syndrome treatment options.

Traditional Approaches for Nephrotic Syndrome Treatment: Steroids and Immunosuppressants

Currently, nephrotic syndrome treatment remains largely non-specific, as there are no universally approved therapies designed exclusively for nephrotic syndrome. As a result, the treatment of nephrotic syndrome often relies on off-label use of established drugs. Common nephrotic syndrome medications include corticosteroids such as prednisone, along with immunosuppressive agents like cyclophosphamide and cyclosporine, which are widely used to induce remission. Supportive nephrotic syndrome management includes diuretics to control edema and ACE inhibitors or angiotensin II receptor blockers to reduce proteinuria, an important aspect of the management of nephrotic syndrome.

Importantly, the choice among available nephrotic syndrome treatment options depends on the underlying kidney pathology. For example, corticosteroids are highly effective in minimal change disease, whereas only a subset of patients with focal segmental glomerulosclerosis respond favorably. In such cases, physicians often turn to combination drugs for nephrotic syndrome, including prednisone, cyclosporine, and cyclophosphamide. For idiopathic membranous nephropathy, treatments for nephrotic syndrome typically involve corticosteroids combined with alkylating agents like chlorambucil or cyclophosphamide. In patients who relapse or show resistance to steroids, rituximab, an advanced nephrotic syndrome immunosuppressive drug targeting CD20-positive B cells, has demonstrated strong efficacy by reducing antibody production.

Beyond traditional medications for nephrotic syndrome, targeted therapies have emerged for specific etiologies. In lupus nephritis, drugs such as BENLYSTA (belimumab) and LUPKYNIS (voclosporin) represent a newer wave of nephrotic syndrome drugs with regulatory approvals. Similarly, in IgA nephropathy, agents like FILSPARI (Sparsentan) and NEFECON (budesonide) expand the landscape of new treatment for nephrotic syndrome. Additionally, INVOKANA (Canagliflozin), an SGLT2 inhibitor, is increasingly used in diabetic nephropathy, reflecting innovation within the broader nephrotic drugs segment and influencing trends in the US proteinuria treatment market.

While the question “nephrotic syndrome can be cured” depends on the underlying cause, many cases can achieve remission with appropriate treatment for nephrotic syndrome. However, long-term monitoring and tailored therapy remain essential. It is also important to distinguish this from nephritic syndrome treatment, as the treatment of nephritic syndrome follows a different clinical approach.

Overall, understanding evolving nephrotic syndrome treatments, including both conventional and emerging nephrotic syndrome medicine, is critical for optimizing patient outcomes and navigating the future of nephrotic syndrome management.

Nephrotic Syndrome Pipeline Therapies: Hope on the Horizon

Companies worldwide are actively advancing the nephrotic syndrome pipeline, focusing on innovative approaches to improve the treatment of nephrotic syndrome and expand available nephrotic syndrome treatment options. The growing body of nephrotic syndrome news highlights a robust portfolio of emerging therapies, including inaxaplin (Vertex Pharmaceuticals), GAZYVA/GAZYVARO (obinutuzumab) (Roche), apecotrep (BI 764198) (Boehringer Ingelheim), and others.

Inaxaplin (formerly VX-147) represents a promising new treatment for nephrotic syndrome. It is an oral, small-molecule APOL1 inhibitor designed to address the root cause of APOL1-mediated kidney disease (AMKD), including FSGS. As the first therapy targeting this underlying mechanism, it marks a significant step forward in nephrotic syndrome management and raises optimism around whether nephrotic syndrome can be cured in specific patient populations. 

In September 2025, Vertex completed enrollment in the IA cohort of the AMPLITUDE Phase II/III trial, assessing its impact on kidney function and proteinuria. The therapy has already received Breakthrough Therapy Designation from the US FDA and PRIME designation from the EMA, reinforcing its potential to redefine nephrotic syndrome medications and drugs for nephrotic syndrome.

Another key candidate, apecotrep (BI 764198), is an oral TRPC6 inhibitor being developed for FSGS. As a potential first-in-class, non-immunosuppressive therapy, it represents a shift beyond traditional nephrotic syndrome immunosuppressive drug approaches. In January 2026, Phase II data demonstrated a 40% reduction in proteinuria at the 20 mg dose versus placebo, highlighting its potential role among nephrotic drugs and drugs used in nephrotic syndrome. The therapy has also received orphan drug designation from both the EMA and Japan’s MHLW, further strengthening its position in the evolving treatment for nephrotic syndrome landscape.

Roche’s GAZYVA/GAZYVARO (obinutuzumab), a glycoengineered anti-CD20 monoclonal antibody, is also gaining traction as part of advanced nephrotic syndrome treatments. By targeting B cells and enhancing antibody-dependent cellular cytotoxicity, it offers a novel mechanism for disease control. In February 2026, positive Phase III results from the MAJESTY trial in primary membranous nephropathy reinforced its potential as a key addition to medications for nephrotic syndrome and broader nephrotic syndrome medicine strategies. Its success also signals continued innovation in immune-modulating approaches, which overlap with nephritic syndrome treatment and treatment of nephritic syndrome paradigms.

Overall, the expanding pipeline of nephrotic syndrome drugs is set to significantly impact both clinical practice and the US proteinuria treatment market. As these therapies progress toward regulatory approval, they are expected to transform the management of nephrotic syndrome, offering more targeted, effective, and personalized treatments for nephrotic syndrome. This wave of innovation not only enhances the current standard of care but also brings the field closer to achieving a functional nephrotic syndrome cure, unlocking new opportunities for patients, clinicians, and the broader healthcare ecosystem.

Precision Medicine: Tailoring Nephrotic Syndrome Treatment to Individuals

Precision medicine is transforming the treatment of nephrotic syndrome by shifting away from generalized care toward highly individualized strategies. By integrating insights from a patient’s genetic profile, environmental influences, and disease-specific characteristics, clinicians can refine nephrotic syndrome treatment options and develop more targeted interventions. This approach enables a clearer distinction between treatment of nephritic syndrome and nephrotic conditions, ensuring that therapies are aligned with the underlying pathology. Whether the focus is on immune modulation, genetic drivers, or metabolic factors, treatment for nephrotic syndrome becomes more precise, improving both efficacy and safety.

Advanced diagnostic tools, including biomarker profiling and genomic testing, are redefining how nephrotic syndrome medications and drugs for nephrotic syndrome are selected. These innovations support the identification of optimal nephrotic syndrome drugs, reducing reliance on trial-and-error and enabling clinicians to personalize medications for nephrotic syndrome based on predicted response and tolerance. As a result, both established nephrotic drugs and new treatment for nephrotic syndrome approaches are being deployed more strategically, enhancing outcomes while minimizing adverse effects.

This evolution also strengthens the broader management of nephrotic syndrome, allowing for dynamic adjustments in therapy, dosing, and supportive care. From selecting the right medication for nephrotic syndrome to optimizing long-term nephrotic syndrome management, precision medicine ensures that care pathways remain adaptive and patient-centric. The growing innovation pipeline, alongside insights from the US proteinuria treatment market, continues to expand the range of nephrotic syndrome treatments and treatments for nephrotic syndrome, reinforcing a future where care is both evidence-based and highly personalized.

Ultimately, precision-driven strategies empower clinicians to deliver the most effective drugs used in nephrotic syndrome, improve quality of life, and redefine expectations for long-term disease control through smarter, more individualized care.

Challenges and Future Directions in Nephrotic Syndrome Treatment

A major challenge in the treatment of nephrotic syndrome is the significant variability in patient response. Although corticosteroids remain the cornerstone among nephrotic syndrome treatment options, many patients fail to achieve adequate remission or eventually develop resistance or dependence. This drives the need for alternative nephrotic syndrome medications, including immunosuppressive agents such as cyclosporine and tacrolimus. However, the prolonged use of such drugs for nephrotic syndrome is associated with serious risks, including infections, hypertension, and nephrotoxicity, highlighting the delicate balance required in the management of nephrotic syndrome. Similar complexities are observed in the treatment of nephritic syndrome, where therapeutic decisions must carefully weigh efficacy against long-term safety.

From a market perspective, the evolving landscape of nephrotic syndrome treatments is reflected in the growing proteinuria treatment market and broader nephrotic syndrome market. According to DelveInsight’s proteinuria treatment market analysis, the total market size of nephrotic syndrome in the 7MM was approximately USD 400 million in 2025. It is expected to grow at a significant CAGR, reaching a notable value by the end of 2036. The US proteinuria treatment market accounted for the largest nephrotic syndrome treatment market share, contributing nearly 50% in 2025, underscoring its dominance and the ongoing demand for advanced treatments for nephrotic syndrome. Emerging proteinuria treatment market trends further indicate a shift toward targeted and personalized therapies.

Ramandeep Singh, Senior Consultant, Forecasting at DelveInsight, forecasts market growth due to the introduction of emerging therapies, expecting a rise in market size during the study period (2022–2036). The anticipated increase in market size, Singh said, is driven by advancements in treatment options, greater healthcare access, and a rising prevalence of the condition, which together foster higher demand for innovative and effective therapies.

Looking ahead, advancements in precision medicine are poised to transform nephrotic syndrome management. A deeper understanding of molecular pathways is enabling the development of new treatment for nephrotic syndrome, including biologics and monoclonal antibodies that may redefine current standards of care. Innovations in nephrotic drugs and next-generation nephrotic syndrome drugs are expected to improve both efficacy and safety profiles. 

Additionally, genetic profiling is emerging as a powerful tool to tailor medications for nephrotic syndrome, allowing more personalized and effective treatment for nephrotic syndrome while minimizing adverse effects. Continued collaboration among researchers, clinicians, and industry stakeholders will be critical to advancing these innovations and shaping the future of nephrotic syndrome medicine.

FAQs